SSRN Electronic Journal
2026
Jake Payne, Arthur Pont, Jacob S. Aday et al.
Background: Emerging adults between 18 and 29, particularly males, are the predominant naturalistic consumers of classic psychedelic substances compared to all other demographics. Previous evidence suggests psychedelic use may interact with positive developmental outcomes and processes. Despite the high prevalence of psychedelic use by emerging adults, limited previous research has...
Brain Behav
November 1, 2025
Jake Payne, Oliver Robinson, Kevin O. St. Arnaud et al.
3 citations
Preliminary evidence suggests that classic psychedelics may exert lasting positive effects on individuals' mood, cognition, and personality, but little is known about how these effects may differ across the lifespan. Emerging adulthood (18-29) is a critical developmental stage in which individuals transition from dependence on community institutions toward full independence. It is a time when...
BMJ Open
May 1, 2024
Ben Beaglehole, Richard Porter, Katie Douglas et al.
5 citations
Although short-term benefits follow parenteral ketamine for treatment-resistant major depressive disorder (TR-MDD), there are challenges that prevent routine use of ketamine by clinicians. These include acute dissociative effects of parenteral ketamine, high relapse rates following ketamine dosing and the uncertain role of psychotherapy. This randomised controlled trial (RCT) seeks to establish...
Front Psychiatry
September 28, 2023
Lauren Johansen, Paul Liknaitzky, Maja Nedeljkovic et al.
5 citations
How psychedelic-assisted therapy works for depression: expert views and practical implications from an exploratory Delphi study.
Syst Rev
May 5, 2022
Lauren Johansen, Paul Liknaitzky, Maja Nedeljkovic et al.
9 citations
BACKGROUND: There is currently renewed interest in the use of psychedelic therapy in the treatment of psychiatric disorders, including depression. The proposed systematic review will aim to identify, evaluate and summarise the psychological processes of change underlying psychedelic therapy for depression in the current literature and consider the implications these processes may have on the...
Australian & New Zealand Journal of Psychiatry
March 21, 2021
Daniel Perkins, Jerome Sarris, Susan L. Rossell et al.
53 citations
The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the ‘Clinical Memorandum on...
Australian & New Zealand Journal of Psychiatry
November 22, 2019
Sally Meikle, Paul Liknaitzky, Susan L. Rossell et al.
19 citations
In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use in the clinical environment,...
Lauren Johansen, Paul Liknaitzky, Maja Nedeljkovic et al.
Abstract BackgroundThere is currently renewed interest in the use of psychedelic therapy in the treatment of psychiatric disorders, including depression. The proposed systematic review will aim to identify, evaluate and summarise the psychological processes of change underlying psychedelic therapy for depression in the current literature and consider the implications these processes may have on...